News & Media

Press release
Notice of Annual General Meeting of Medivir AB (publ)

The shareholders of Medivir AB are hereby summoned to the annual general meeting on Tuesday 5 May 2020 at 2 p.m....

Read more
Press release
Medivir and Tango Therapeutics sign license agreement for preclinical asset

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announced that it has entered into a license agreement with US biotech...

Read more
Press release
First liver cancer patient dosed in the MIV-818 phase Ib study

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announced that the first patient with advanced liver cancer has been dosed...

Read more
Press release
Medivir presents positive data from the completed phase Ia study with MIV-818 in patients with advanced liver cancer

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) announces that new data from the completed phase Ia study with MIV-818 will...

Read more
Press release
Invitation to Medivir's R&D Day on March 2, 2020

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) invites investors, analysts and the media to a R&D Day in Stockholm, Monday...

Read more
Press release
Medivir and Shijiazhuang Yuanmai Biotechnology sign licensing agreement regarding manufacturing and sales of Xerclear® in China

Stockholm — Medivir AB (Nasdaq Stockholm: MVIR) announces today that the company has signed a licensing agreement for Medivir's Xerclear® for...

Read more
Press release
MEDIVIR AB – YEAR END REPORT JANUARY – DECEMBER 2019

Continued progress with our proprietary and wholly owned candidate drug MIV-818 for liver cancer October – December Significant events during the...

Read more
Press release
Medivir invites to R&D Day on March 2, 2020

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) invites investors, analysts and the media to an R&D Day in Stockholm, Monday...

Read more
Press release
Medivir has received notices of allowance in the EU and Japan for MIV-818 patent applications

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) reports that the MIV-818 patent portfolio has been reinforced by the issue of...

Read more
Press release
Medivir´s phase II study of MIV-711 in patients with osteoarthritis published in Annals of Internal Medicine

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) announces that the phase II study of MIV-711 in patients with osteoarthritis has...

Read more